The binding energy of caffeoyl tartaric acid to the core target IL6 and neo aconitine to the core target TNF is also less than −7 kcal·mol−1, which suggests that the active ingredients of the formula can be better combined with the core target of CKD, and the potential biological activity is higher. The gene discussed is IL6; the disease is chronic kidney disease.